Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

[/toggle]

ACADIA Pharmaceuticals $ACAD started a Phase 3 study, dubbed as ENHANCE-1, evaluating NUPLAZID (pimavanserin) for adjunctive treatment of schizophrenia in patients who have failed to respond to antipsychotic therapy, a symptom that affects roughly 30% of schizophrenia victims.

Mast Therapeutics’ mid-stage study on pulmonary hypertension shows positive results-Mast Therapeutics $MSTX announced positive preliminary results from an open-label Phase 2 clinical trial evaluating now-lead product candidate AIR001 for the treatment of pulmonary hypertension (PH). The data was published in the Journal of Clinical Investigation. It showed that 36 patients receiving AIR001 (sodium nitrite solution for intermittent inhalation) witnessed decreases in pulmonary, right atrial and pulmonary capillary wedge pressures.

Gilead discontinues development of few pipeline candidates-Gilead Sciences $GILD has discontinued with some of its pipeline programs: Selonsertib (GS-4997), an ASKI inhibitor in Phase 2 development for the treatment of alcoholic hepatitis, NASH, pulmonary arterial hypertension and diabetic kidney disease, had stopped midway; and so has GS-6624 (simtuzumab), targeting an enzyme called lysyl oxidase-like-2 (LOXL2), under development for the treatment of NASH and primary sclerosing cholangitis got halted. The drug-maker has also ended development of GS-5745, an anti-MMP9 antibody, for the treatment of Crohn’s and ulcerative colitis and GS-6615 (eleclazine) for ventricular tachycardia/fibrillation.

 Achillion plunges; PNH candidate ACH-4481 raises potential safety issues-Achillion Pharmaceuticals $ACHN plunged amid more than triple normal trading volume in response to a report of Phase 1 data from ACH-4471, a factor D inhibitor in development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The initial-stage clinical trial explored the safety, pharmacodynamics and pharmacokinetics of ACH-4471. Safety concerns got raised when it was found that there were two cases of self-limited grade 3 (5 - 10x the upper limit of normal or ULN) and grade 4 (greater than 10x ULN) elevations in a liver enzyme called alanine transaminase (ALT) which is a biomarker of liver damage.

 Translarna uncertainty over availability in Europe hammers PTC’s shares-PTC Therapeutics $PTCT got hammered on Thursday amid more than triple normal trading volume in response to its statement that regarding ongoing availability of Duchenne muscular dystrophy med Translana (ataluren) in Europe. The company disclosed that during its October meeting with the advisory committee CHMP, it was asked for additional information concerning the risk-benefit profile of the treatment.

No approvals to report.

No patents to report.

Allergan’s $AGN planned $640 million acquisition of Vitae Pharmaceuticals, which was likely to close this quarter, apparently has hit a roadblock after analysts reported that one of its two main pipeline candidates VTP-38543, failed to show a treatment benefit in a Phase 2 clinical trial in atopic dermatitis. It now only has one medium-term candidate in development, psoriasis med VTP-43742. Earlier in September, $AGN announced its acquisition plans at a premium of 160%, at that moment.

No secondary offerings to report.

No IPOs to report.

Translarna, its efficacy and the design of a pivotal trial that would provide comprehensive data. Although the drug-maker has responded to CHMP’s requests, it adds that the “recent dialogue has introduced a higher degree of uncertainty as to the outcome” [of its renewal].

Nektar Therapeutics $NKTR reported Q3 EPS of -$0.32, beating the guidance by $0.04. Revenue was $36.34 million, a drop of 39.4% Y-o-Y, but beating the estimate by $3.92 million.

Xenon Pharma $XENE posted Q3 EPS of -$0.51, missing the guidance by $0.08. Revenue was $0.40 million, a drop 90.4%, missing the guidance by $1.79 million.

Exelixis $EXEL reported Q3 EPS of -$0.04, beating the guidance by $0.09. Revenue was $62.19 million, a jump of 531.4% Y-o-Y and beating the estimate by $19.33 million.

Aviragen Therapeutics $AVIR reported Q1 EPS of -$0.26, beating the guidance by $0.02. Revenue was $0.1 million, a drop of 94.1% Y-o-Y and missing the estimate by $0.47 million.

Tesaro $TSRO reported Q3 EPS of -$1.98 missing the guidance by $0.06. Revenue was $3.73 million, a growth of 4044.4%, Y-o-Y but missing the estimate by $0.66 million.

Revance Therapeutics $RVNC reported Q3 EPS of -$0.64, beating the guidance by $0.25. Revenue was $0.08 million, which was flat Y-o-Y, but beating the guidance by $0.01 million.

Inogen $INGN reported Q3 EPS of $0.16 beating the guidance by $0.03. Revenue was $54.42 million, a growth of 33.4% Y-o-Y and beating $6.53 million.

Oncolytics Biotech $ONCYF reported financial results of Q3. For the quarter ended September 30, 2016, EPS was -$0.03. As of September, the company had $17.7 million in cash, cash equivalents, and short term investments and as of November 2, 2016, it had roughly $16.7 million in cash, cash equivalents and short-term investments.

Epizyme $EPZM reported Q3 results. For the quarter, EPS was -$0.42, beating the guidance by $0.18. Revenue was $6.58 million, a 172.8% growth Y-o-Y and beating the estimate by $6.11 million.

Sage Therapeutics $SAGE reported Q3 EPS of -$1.15, missing the guidance by $0.05. Cash and cah equivalents were at $320.1 million as of September 30, 2016.

Radius Health $RDUS posted a net loss of $46.2 million or -$1.07 a share, missing the guidance by $0.04. The company reported a net loss of $28.3 million or -$0.68 a share in the corresponding period of last year. The rise in net loss for the three months ended September 30, 2016 as compared to the three months ended September 30, 2015 was mainly due to higher research and development and general and administrative expenses, partially offset by a decrease in loss on retirement of note payable, a decrease in interest expense and an increase in interest income.

Amarin $AMRN posted Q3 EPS of -$0.08, beating the guidance by $0.02. Revenue for the quarter was $32.77, a growth of 52.4% Y-o-Y, and beating the guidance by $0.7 million.

Vical $VICL reported Q3 revenue of $2.64 million, a plunge of 47.4%, Y-o-Y and missing the guidance by $1.96 million. EPS was -$0.24 beating the forecast by $0.01. The company’s net cash used for the nine months period of 2016 was $6.8 million, which was in-line with company’s guidance for the full-year. It has projected a net cash burn for 2016 between $8 million and $11 million.